CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 23 enrolled
Drug / intervention
Bromfenac +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01310127
NCT01310127Phase 4Completed
CompareCT.gov

Clinical Outcomes of Bromday (Bromfenac Ophthalmic Solution) 0.09% QD vs. Nevanac (Nepafenac Ophthalmic Suspension) 0.1% TID for Treatment of Ocular Inflammation Associated With Cataract Surgery

Toyos Clinic·interventional·Posted Mar 8, 2011·Updated Oct 28, 2020

In Brief

A Phase 4 clinical trial evaluating Bromfenac and Nepafenac for Inflammation and Pseudophakia. Completed, enrolled 23 participants.

Detailed Summary

This is a single-center, randomized, investigator-masked, parallel group, and active-comparator controlled study investigating the clinical outcomes for visual acuity and macular thickness after treatment with Bromday (bromfenac ophthalmic solution) 0.09% QD or Nevanac (nepafenac ophthalmic suspension) 0.1% TID in subjects who have undergone cataract extraction with posterior chamber intraocular lens implantation.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInflammation, Pseudophakia
Countries--
CollaboratorsBausch & Lomb Incorporated

Timeline

Phase 4CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedMar 8, 2011
Enrollment StartNov 1, 2010
Primary CompletionApr 1, 2011
Study CompletionMay 1, 2011
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 15.3 years ago

Interventions

Bromfenacdrug

bromfenac 0.9% QD starting 3 days prior to cataract surgery, on the day of surgery and for up to 45 days after surgery

Nepafenacdrug

nepafenac ophthalmic suspension 0.1% TID dosed 3 days prior to cataract surgery, on the day of surgery, and for up to 45 days after surgery